Regeneron Pharmaceuticals REGN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's total equity?
- Regeneron Pharmaceuticals (REGN) reported total equity of $31.42B in Q1 2026.
- How has Regeneron Pharmaceuticals's total equity changed year-over-year?
- Regeneron Pharmaceuticals's total equity increased by 6.9% year-over-year, from $29.39B to $31.42B.
- What is the long-term trend for Regeneron Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total equity has grown at a 23.2% compound annual growth rate (CAGR), from $11.03B to $31.26B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.